|
1
|
Hori M, Matsuda T, Shibata A, Katanoda K,
Sobue T and Nishimoto H; Japan Cancer Surveillance Research Group,
: Cancer incidence and incidence rates in Japan in 2009: A study of
32 population-based cancer registries for the Monitoring of Cancer
Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 45:884–891.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim HJ and Oh SC: Novel systemic therapies
for advanced gastric cancer. J Gastric Cancer. 18:1–19. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39:10104283177146262017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Turano C, Gaucci E, Grillo C and
Chichiarelli S: ERp57/GRP58: A protein with multiple functions.
Cell Mol Biol Lett. 16:539–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ni M and Lee AS: ER chaperones in
mammalian development and human diseases. FEBS Lett. 581:3641–3651.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hettinghouse A, Liu R and Liu CJ:
Multifunctional molecule ERp57: From cancer to neurodegenerative
diseases. Pharmacol Ther. 181:34–48. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choe MH, Min JW, Jeon HB, Cho DH, Oh JS,
Lee HG, Hwang SG, An S, Han YH and Kim JS: ERp57 modulates STAT3
activity in radioresistant laryngeal cancer cells and serves as a
prognostic marker for laryngeal cancer. Oncotarget. 6:2654–2666.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takata H, Kudo M, Yamamoto T, Ueda J,
Ishino K, Peng WX, Wada R, Taniai N, Yoshida H, Uchida E, et al:
Increased expression of PDIA3 and its association with cancer cell
proliferation and poor prognosis in hepatocellular carcinoma. Oncol
Lett. 12:4896–4904. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zou H, Wen C, Peng Z, Shao YY, Hu L, Li S,
Li C and Zhou HH: P4HB and PDIA3 are associated with tumor
progression and therapeutic outcome of diffuse gliomas. Oncol Rep.
39:501–510. 2018.PubMed/NCBI
|
|
10
|
Chung H, Cho H, Perry C, Song J, Ylaya K,
Lee H and Kim JH: Downregulation of ERp57 expression is associated
with poor prognosis in early-stage cervical cancer. Biomarkers.
18:573–579. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leys CM, Nomura S, LaFleur BJ, Ferrone S,
Kaminishi M, Montgomery E and Goldenring JR: Expression and
prognostic significance of prothymosin-alpha and ERp57 in human
gastric cancer. Surgery. 141:41–50. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lauren P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sano T, Coit DG, Kim HH, Roviello F,
Kassab P, Wittekind C, Yamamoto Y and Ohashi Y: Proposal of a new
stage grouping of gastric cancer for TNM classification:
International gastric cancer association staging project. Gastric
Cancer. 20:217–225. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou F: Molecular mechanisms of IFN-gamma
to up-regulate MHC class I antigen processing and presentation. Int
Rev Immunol. 28:239–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu
S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic
landscape and genetic heterogeneity in gastric adenocarcinoma
revealed by whole-genome sequencing. Nat Commun. 5:54772014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Doroudi M, Olivares-Navarrete R, Boyan BD
and Schwartz Z: A review of 1α,25(OH)2D3
dependent Pdia3 receptor complex components in Wnt5a non-canonical
pathway signaling. J Steroid Biochem Mol Biol. 152:84–88. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gaucci E, Altieri F, Turano C and
Chichiarelli S: The protein ERp57 contributes to EGF receptor
signaling and internalization in MDA-MB-468 breast cancer cells. J
Cell Biochem. 114:2461–2470. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coe H, Jung J, Groenendyk J, Prins D and
Michalak M: ERp57 modulates STAT3 signaling from the lumen of the
endoplasmic reticulum. J Biol Chem. 285:6725–6738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramirez-Rangel I, Bracho-Valdés I,
Vázquez-Macías A, Carretero-Ortega J, Reyes-Cruz G and
Vázquez-Prado J: Regulation of mTORC1 complex assembly and
signaling by GRp58/ERp57. Mol Cell Biol. 31:1657–1671. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li CW, Chang PY and Chen BS: Investigating
the mechanism of hepatocellular carcinoma progression by
constructing genetic and epigenetic networks using NGS data
identification and big database mining method. Oncotarget.
7:79453–79473. 2016.PubMed/NCBI
|
|
24
|
Katona BW and Rustgi AK: Gastric cancer
genomics: Advances and future directions. Cell Mol Gastroenterol
Hepatol. 3:211–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blees A, Januliene D, Hofmann T, Koller N,
Schmidt C, Trowitzsch S, Moeller A and Tampé R: Structure of the
human MHC-I peptide-loading complex. Nature. 551:525–528.
2017.PubMed/NCBI
|
|
26
|
Garbi N, Hämmerling G and Tanaka S:
Interaction of ERp57 and tapasin in the generation of MHC class
I-peptide complexes. Curr Opin Immunol. 19:99–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Lin J, Guo ZQ, Lin WS, Zhou ZF,
Huang CZ, Chen Q and Ye YB: MHC I-related chain a expression in
gastric carcinoma and the efficacy of immunotherapy with
cytokine-induced killer cells. Am J Cancer Res. 5:3221–3230.
2015.PubMed/NCBI
|
|
28
|
Ribeiro CH, Kramm K, Gálvez-Jirón F, Pola
V, Bustamante M, Contreras HR, Sabag A, Garrido-Tapia M, Hernández
CJ, Zúñiga R, et al: Clinical significance of tumor expression of
major histocompatibility complex class I-related chains A and B
(MICA/B) in gastric cancer patients. Oncol Rep. 35:1309–1317. 2016.
View Article : Google Scholar : PubMed/NCBI
|
